Tag Archives: genzyme

December, 2017

October, 2017

September, 2017

  • 20 September

    Alnylam’s Rare Disease Drug Meets Endpoints in Late-Stage hATTR Amyloidosis Study

    CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, and Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR amyloidosis with polyneuropathy, met its primary efficacy endpoint …

July, 2017

April, 2017

November, 2016

June, 2015

  • 8 June

    Breakthrough Status Granted to Genzyme’s Rare Enzyme Replacement Drug

    Genzyme, a Sanofi company, recently announced that its investigational enzyme-replacement therapy was granted Breakthrough Therapy designation from US health regulators. The company said that the agency granted the status to its olipudase alfa for the treatment of patients with nonneurological manifestations of acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick …

April, 2015

February, 2015